Clinical benefit of NMDA receptor antagonists in a patient with ATP1A2 gene mutation

Keyphrases

• Gene mutation 100%
• Clinical Benefit 100%
• NMDA Receptor Antagonist 100%
• ATP1A2 Gene 100%
• Fine Motor 40%
• Clinical Significance 20%
• Whole Exome Sequencing 20%
• Seizure 20%
• Receptor Antagonist 20%
• Attention Deficit Hyperactivity Disorder 20%
• Intellectual Disability 20%
• N-methyl-D-aspartate 20%
• Glutamate Excitotoxicity 20%
• Early childhood 20%
• Epilepsy 20%
• Behavioral Symptoms 20%
• Cognitive Symptoms 20%
• Right-sided 20%
• Missense mutation 20%
• Patient Condition 20%
• Hemiplegia 20%
• Antiepileptic Drugs 20%
• Hemiparesis 20%
• Motor Impairment 20%
• Cerebellar Function 20%
• Glutamatergic 20%
• N-methyl-D-aspartate Receptor Antagonist 20%
• 12-year-olds 20%
• Memantine 20%
• Hyperexcitability 20%
• Cerebellar Degeneration 20%
• Coenzyme Q10 20%
• Focal Epilepsy 20%
• Sustained Attention 20%
• Valproate 20%
• Fine Motor Skills 20%
• Maternally Inherited 20%
• Dextromethorphan 20%
• Motor Difficulties 20%
• Learning Efficiency 20%
• General Cognitive 20%
• Attention Learning 20%
• Complex Partial Seizures 20%
• Familial Hemiplegic Migraine 20%
• Cognitive Efficiency 20%
• Executive Deficits 20%
• Alternating Hemiplegia of childhood 20%
• POLG Gene 20%

Neuroscience

• NMDA Receptor Antagonist 100%
• Gene Mutation 100%
• Hemiplegia 66%
• Excitotoxicity 33%
• Attention Deficit Hyperactivity Disorder 33%
• Receptor Antagonist 33%
• Stereotypic Movement Disorder 33%
• Exome Sequencing 33%
• Hemiparesis 33%
• Memantine 33%
• Missense Mutation 33%
• Familial Hemiplegic Migraine 33%
• Focal Epilepsy 33%
• Coenzyme 33%
• Complex Partial Seizure 33%
• Dextromethorphan 33%
• Anticonvulsant 33%